Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population

(2018) Soo-Yon Rhee et al.   CLINICAL INFECTIOUS DISEASES

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial

(2018) Jose L Blanco et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Epidemiology of HIV drug resistance in HIV patients with virologic failure of first-line therapy in the country of Georgia

(2018) Ekaterine Karkashadze et al.   JOURNAL OF MEDICAL VIROLOGY

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

(2018) Jean-Michel Molina et al.   Lancet HIV

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

(2018) Eric S Daar et al.   Lancet HIV

Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study

(2018) Chien-Yu Cheng et al.   Infection and Drug Resistance

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2018) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

(2017) Joel E. Gallant et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide

(2017) Nicolas A. Margot et al.   JOURNAL OF INFECTIOUS DISEASES

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial

(2017) Ingeborg Wijting et al.   Lancet HIV

Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants

(2016) M. Noguera-Julian et al.   CLINICAL MICROBIOLOGY AND INFECTION

Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia

(2016) C. Katlama et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation

(2016) Kenny Dauwe et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Reduced Viral Fitness and Lack of Cross-Class Resistance with Integrase Strand Transfer Inhibitor and Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations

(2015) Kristen N. Andreatta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions

(2015) Kristen N. Andreatta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure

(2013) Ya-Chi Ho et al.   CELL

Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003–2010

(2012) Michael D Miller et al.   ANTIVIRAL THERAPY

APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” Phenomenon

(2012) Andrew E. Armitage et al.   PLoS Genetics

Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia

(2011) M. Wirden et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

(2011) Linda Wittkop et al.   LANCET INFECTIOUS DISEASES

Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa

(2008) Vincent C. Marconi et al.   CLINICAL INFECTIOUS DISEASES